Alder Announces Presentations at the European Headache and Migraine Trust International Congress Supporting Development of ALD403 for Migraine Prevention

BOTHELL, Wash., Sept. 08, 2016 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that data from Phase 2b and Phase 1 clinical trials of ALD403 supporting development for the prevention of migraine, and preclinical data from a case study of ALD403 and other CGRP-antibodies will be presented at the upcoming 5th European Headache and Migraine Trust International Congress (EHMTIC 2016) on September 15-18, 2016 in Glasgow, U.K.

• Poster presentation: “Randomized, Double-Blind, Placebo-Controlled Trial of ALD403, an Anti-CGRP Peptide Antibody in the Prevention of Chronic Migraine”
  
  Poster #: EHMTC-0410
  Session Title: Poster Discussion Session A
  Session Date: Friday, September 16, 2016
  Session Time: 1:00 am – 12:30 pm BST
  
  

• Poster presentation: “A Multiple-Dose, Phase I Placebo-Controlled, Randomized Study of ALD403, An Anti-CGRP Antibody, Administered Every 3-Months via IV, SC, or IM”
  
  Poster #: EHMTC-0397
  Session Title: Poster Discussion Session A
  Session Date: Friday, September 16, 2016
  Session Time: 11:00 am – 12:30 pm BST
  
  

• Poster presentation: “Characterization of the Binding of Three Anti-CGRP Antibodies Effective in Preventing Migraine: A Comparative Case Study of ALD403, LY-2951742, TEV-48125”
  
  Poster #: EHMTC-0359
  Session Title: Poster Discussion Session E
  Session Date: Saturday, September 17, 2016
  Session Time: 6:30 pm – 7:30 pm BST
  
  

About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, ALD403, is being evaluated for migraine prevention. ALD403 is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.

Media Contacts:			
David Schull or Todd Davenport, Ph.D.	
Russo Partners, LLC			
(212) 845-4271				
(212) 845-4235				
[email protected] 
[email protected] 

Investor Relations Contact:
David Walsey
Alder BioPharmaceuticals
(425) 408-8032
[email protected]